Australian hospitals have grappled with a concerning increase in emergencies related to Ozempic overdoses. The Victorian Poisons Information Centre has reported a staggering 82 related calls within the span of two years, shedding light on a worrisome trend that demands urgent attention. The data, which underscores a sharp rise in incidents, raises questions about the safety and administration of this medication.
A critical revelation from the Victorian Poisons Information Centre is that a significant 74 per cent of the emergency calls were attributed to medication administration errors.
This statistic highlights a prevalent issue with the handling and dispensing of Ozempic, a medication prescribed for managing type 2 diabetes. The majority of these incidents were not a result of intentional misuse but rather a consequence of errors made during the administration process.
Semaglutide, sold under the brand name Ozempic and originally approved for managing type 2 diabetes, is experiencing a growing trend of “off-label” prescription for weight loss.
However, this practice is imposing a financial burden on patients, with costs exceeding $130 per month. The drug, designed for weekly injections, has encountered issues in its administration, resulting in errors that have compelled some individuals to seek emergency care at hospital departments.
These occurrences are not singular; they mirror a tragic narrative involving an Australian mother who lost her life after using Ozempic. Trish Webster, a 56-year-old woman endeavouring to shed weight for her daughter’s wedding, succumbed to the repercussions of combining the drug with Saxenda, another diabetes medication repurposed for weight loss.
